Cancer
01 Jan 2013
Combination Chemotherapy After Surgery in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective after surgery in treating breast cancer. PURPOSE: Randomized phase III trial to compare different combination chemotherapy regimens…
Cancer
01 Jan 2013
A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer
The purpose of this study is to determine the side-effects and effectiveness of a new type of chemoradiotherapy treatment for patients who have had surgery for stomach cancer. The treatment uses epirubicin, cisplatin, and 5-fluorouracil (ECF) chemotherapy together with radiotherapy. Official Title Conditions Gastric Cancer Study Type Interventional Study Design…
Cancer
01 Jan 2013
Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer
The aim of this study was to evaluate the efficacy and toxicity of a new combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in the treatment of metastatic urothelial cancer. Official Title Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. Conditions…
Cancer
01 Jan 2013
Study of irinotecan (CPT-11) combined with fixed dose of 5-fluorouracil (5-FU) adult patients with advanced solid tumours
Advanced solid tumors (gastrointestinal incl. Colorectal, head & neck, others) (1): to find the maximum tolerated dose (MTD) of the combined chemotherapy. (2): to determine the quantitive and qualitative toxic effects, the Dose-limiting toxicity and the recommended dose for phase II trials. (3): to define the safety profile…
Cancer
01 Jan 2013
Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer
Advanced colorectal cancer (ACRC) To determine complete resection (R0), response rate, time to progression (TTP) and overall survival (OS) in patients with non-resectable ACRC after being treated with neoadjuvant irinotecan-based chemotherapy. Official Title Conditions Study Type Retrospective analysis Study Design Further Details Treatment Details:Irinotecan 250 mg/m2 i.v. (1h)…
Cancer
01 Jan 2013
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities
Advanced colorectal cancer. To establish the dose-limiting toxicities and maximum-tolerated dose of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in combination with FOLFIRI, a standard regimen of irinotecan, leucovorin, and infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer. Official Title Conditions Study Type…
Cancer
01 Jan 2013
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
RATIONALE: Sulindac may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Hormone therapy using tamoxifen may fight cancer by blocking the uptake of estrogen. Combining sulindac with tamoxifen may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining…
Cancer
01 Jan 2013
Treatment of non-Hodgkin’s lymphoma with rituximab plus CHOP chemotherapy: 9-year follow-up
The objective of the study was to present long-term follow-up data with updated time to disease progression (TTP) and duration of response (DR) from a multicenter, phase II trial of R-CHOP combination therapy in 40 patients with CD20+, B-cell NHL. Primary endpoints: ORR, PR rate and CR rate; secondary endpoints:…
Cancer
01 Jan 2013
Anti-angiogenesis Agent AG-013736 in Patients with Metastatic Melanoma
This is a Phase 2 study being conducted at multiple centers in the United States. Patients having melanoma that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that has been treated with no more than 1 prior treatment for metastatic…
